Geetha Ramaswamy’s scientific contributions

... Nelotanserin (APD-125) is another serotonin 5-HT2A receptor inverse agonist. It was initially studied in a phase 2 study of 30 participants with DLB or PDD who have visual hallucinations, but there was no statistical improvement in any endpoints including the frequency and intensity of visual hallucinations [91]. In a second phase 2 study evaluating participants with DLB or PDD who have REM sleep behavior disorder, only 29 of 60 intended participants were enrolled. ...

Reference:

Lewy Body Dementia: An Overview of Promising Therapeutics

... Similarly, intepirdine (a nonselective 5-HT 6 R antagonist developed by Axovant (initially by GSK)) was also discontinued in 2017 after failure in a phase 3 clinical trial. [21] The failure of 5-HT 6 R antagonists in improving the condition of patients with AD may lie in the insufficient understanding of the role of 5-HT 6 R antagonists in neurodegenerative disorders. [22] Nevertheless, the 5-HT 6 receptor is still a promising target candidate for future medications for cognitive impairments [23] or other symptoms associated with AD-like anxiety and depression. ...

Reference:

Virtual screening-driven discovery of dual 5-HT6/5-HT2A receptor ligands with pro-cognitive properties

... It was examined in Phase III, named MINDSET, but failed to achieve assumed primary outcome, although one of the secondary outcome parameters was found statistically significant, causing notable improvement in the rating of Clinical Global Impression of Change -Plus Caregiver Interview. Phase III MINDSET extension trial was conducted to investigate the safety of intepirdine by performing physical examination and clinical laboratory assessment, but the study was terminated as the main trial did not reach its primary outcome 71,72 . ...

Reference:

Chemical update on the potential for serotonin 5-HT6 and 5-HT7 receptor agents in the treatment of Alzheimer's disease

... Investigational drugs (5-HT6 receptor antagonists) are currently being studied as cognitive enhancers in DLB and other types of dementia [57]. ...

Reference:

Diagnosis and Management of Cognitive and Behavioral Changes in Dementia With Lewy Bodies